Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.670
+0.090 (5.70%)
At close: Mar 9, 2026, 4:00 PM EDT
1.670
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Milestone Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
169.64M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Zentalis Pharmaceuticals | 26.87M |
| Innate Pharma | 14.84M |
| Caribou Biosciences | 11.16M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Fate Therapeutics | 6.65M |
| Rani Therapeutics Holdings | 1.20M |
MIST News
- 11 days ago - Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 27 days ago - Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire
- 7 weeks ago - Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense - Seeking Alpha
- 2 months ago - Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - GlobeNewsWire
- 3 months ago - Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript - Seeking Alpha
- 3 months ago - Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire